Stock Analysis

COLTENE Holding AG (VTX:CLTN) Analysts Are Pretty Bullish On The Stock After Recent Results

There's been a notable change in appetite for COLTENE Holding AG (VTX:CLTN) shares in the week since its annual report, with the stock down 18% to CHF87.90. It looks like the results were a bit of a negative overall. While revenues of CHF279m were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 2.2% to hit CHF5.31 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

See our latest analysis for COLTENE Holding

earnings-and-revenue-growth
SWX:CLTN Earnings and Revenue Growth March 9th 2022

Taking into account the latest results, COLTENE Holding's two analysts currently expect revenues in 2022 to be CHF284.2m, approximately in line with the last 12 months. Statutory earnings per share are predicted to rise 3.3% to CHF5.48. Yet prior to the latest earnings, the analysts had been anticipated revenues of CHF289.9m and earnings per share (EPS) of CHF5.52 in 2022. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

The consensus price target rose 27% to CHF107despite there being no meaningful change to earnings estimates. It could be that the analystsare reflecting the predictability of COLTENE Holding's earnings by assigning a price premium.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that COLTENE Holding's revenue growth is expected to slow, with the forecast 1.8% annualised growth rate until the end of 2022 being well below the historical 13% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 8.1% annually. Factoring in the forecast slowdown in growth, it seems obvious that COLTENE Holding is also expected to grow slower than other industry participants.

Advertisement

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting sales are tracking in line with expectations - although our data does suggest that COLTENE Holding's revenues are expected to perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for COLTENE Holding going out as far as 2024, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for COLTENE Holding that you need to take into consideration.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SWX:CLTN

COLTENE Holding

Develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4039.0% undervalued
6 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6087.9% undervalued
8 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8143.2% undervalued
21 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

NO
S5L logo
Norms70 on Standard Lithium ·

SLI is share to watch next 5 years

Fair Value:€4.57.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
davidlsander
BEAM logo
davidlsander on Beam Therapeutics ·

The "Molecular Pencil": Why Beam's Technology is Built to Win

Fair Value:US$15082.3% undervalued
61 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
RE
PRME logo
RedhawkCC on Prime Medicine ·

PRME remains a long shot but publication in the New England Journal of Medicine helps.

Fair Value:US$0.0469.1k% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
118 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3926.1% undervalued
962 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8696.4% undervalued
75 users have followed this narrative
7 users have commented on this narrative
21 users have liked this narrative